From: Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women
Characteristics |  | BRCA mutant n = 25 (41%) | BRCA wild type n = 36 (59%) | P-Value* |
---|---|---|---|---|
N (Frequency) | N (Frequency) | |||
Age at diagnosis | ||||
Median (IQR) |  | 50 (43–56) | 55 (46–66) | 0.13 |
Age ≤ 50 |  | 14 (56) | 15 (41.7) | 0.27 |
Positive personal history of cancer | Â | 5 (20) | 1 (2.9) | 0.04 |
Positive family history of cancer | Â | 7 (28) | 2 (5.6) | 0.02 |
Presence of comorbidities* | Â | 19 (76) | 24 (66.7) | 0.43 |
Histology | High-grade serous | 25 (100) | 35 (97.1) | 0.39 |
 | Endometrioid |  | 1 (2.9) |  |
High grade FIGO stage | Â | 25 (100) | 34 (94.4) | 0.48 |
 | Stage 1 | 6 | 3 | 0.65 |
 | IA | 2 | 0 |  |
 | IB | 2 | 1 |  |
 | IC | 2 | 2 |  |
 | Stage 2 | 1 | 4 |  |
 | IIA | 1 | 1 |  |
 | IIB | 0 | 3 |  |
 | Stage 3 | 15 (58) | 21 (55) |  |
 | IIIA | 0 | 2 |  |
 | IIIB | 1 | 2 |  |
 | IIIC | 14 | 17 |  |
 | Stage 4 | 4 | 10 |  |
High CA125 (> 35) |  | 20 (80) | 26 (72.2) | 0.46 |
Initial management | PDS | 12 (48) | 18 (50) | 0.87 |
 | NAC | 13 (52) | 18 (50) |  |
No. of lines, median (IQR) |  | 3 (1–5) | 3 (2–4.75) | 0.79 |
Lines of treatment | ||||
First line (n = 61) |  | (n = 25) | (n = 18) |  |
PBC Non PBC | Â | 100% | 100% | 0.26 |
Second line (n = 49) |  | (n = 18) | (n = 31) |  |
PBC | Â | 88.9 | 83.4 | 0.79 |
Non PBC | Â | 11.1 | 16.6 | Â |
Third line (n = 39) |  | (n = 13) | (n = 26) |  |
PBC | Â | 73.1 | 64 | 0.42 |
Non PBC | Â | 26.9 | 36 | Â |
Fourth line (n = 23) |  | (n = 10) | (n = 13) |  |
PBC | Â | 50% | 23.1% | 0.38 |
Non PBC | Â | 50% | 76.9% | Â |
Fifth line (n = 13) |  | (n = 7) | (n = 5) |  |
PBC |  | – | – | 0.68 |
Non PBC | Â | 100% | 100% | Â |